• D Scott LaMontagne, BloemPaul J NPJNWorld Health Organization, Geneva, Switzerland., BrothertonJulia M LJMLNational HPV Vaccination Program Register, VCS Ltd, Melbourne, Vic., Australia.School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia., Katherine E Gallagher, Ousseynou Badiane, and Cathy Ndiaye.
• PATH, Seattle, WA, USA.
• Int J Gynaecol Obstet. 2017 Jul 1; 138 Suppl 1: 7-14.

AbstractThe past 10 years have seen remarkable progress in the global scale-up of human papillomavirus (HPV) vaccinations. Forty-three low- and lower-middle-income countries (LLMICs) have gained experience in delivering this vaccine to young adolescent girls through pilot programs, demonstration programs, and national introductions and most of these have occurred in the last 4 years. The experience of Senegal is summarized as an illustrative country case study. Publication of numerous delivery experiences and lessons learned has demonstrated the acceptability and feasibility of HPV vaccinations in LLMICs. Four areas require dedicated action to overcome remaining challenges to national scaling-up: maintaining momentum politically, planning successfully, securing financing, and fostering sustainability. Advances in policy, programming, and science may help accelerate reaching 30 million girls in LLMICs with HPV vaccine by 2020.© 2017 The Authors. International Journal of Gynecology & Obstetrics published by John Wiley & Sons Ltd on behalf of International Federation of Gynecology and Obstetrics.

18 keywords...

hide…